Iliyana Hristova Petrova

Prof. Dr. Iliyana Hristova Petrova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
IPIliyana Hristova Petrova
Iliyana Hristova Petrova
AAAlexander Alexandrov
Alexander Alexandrov
GVGeorgi Vladimirov
Georgi Vladimirov
HMHristo Mateev
Hristo Mateev
IBIvaylo Bogov
Ivaylo Bogov
NGNina Gotcheva
Nina Gotcheva
Contrast-induced acute kidney injury (CI-AKI) is a serious complication after angiographic examinations in cardiology. Diagnosis may be delayed based on standard serum creatinine, and subclinical forms of kidney damage may not be detected at all. In our study, we investigate the clinical use in these directions of a “damage”-type biomarker—neutrophil gelatinase-associated lipocalin (NGAL). Among patients with a high-risk profile undergoing scheduled coronary angiography and/or angioplasty, plasma NGAL was determined at baseline and at 4th and 24th h after contrast administration. In the CI-AKI group, NGAL increased significantly at the 4th hour (Me 109.3 (IQR 92.1–148.7) ng/mL versus 97.6 (IQR 69.4–127.0) ng/mL, p = 0.006) and at the 24th hour (Me 131.0 (IQR 81.1–240.8) ng/mL, p = 0.008). In patients with subclinical CI-AKI, NGAL also increased significantly at the 4th hour (Me 94.0 (IQR 75.5–148.2) ng/mL, p = 0.002) and reached levels close to those in patients with CI-AKI. Unlike the new biomarker, however, serum creatinine did not change significantly in this group. The diagnostic power of NGAL is extremely good—AUC 0.847 (95% CI: 0.677–1.000; p = 0.001) in CI-AKI and AUC 0.731 (95% CI: 0.539–0.924; p = 0.024) in subclinical CI-AKI. NGAL may be a reliable biomarker for the early diagnosis of clinical and subclinical forms of renal injury after contrast angiographic studies.

22 April 2026 in Journal of Integrative Neuroscience
Verified
Journal Article
Open access
PDF file
SKSpas Kitov
Spas Kitov
TDTanya Deneva
Tanya Deneva
MKMaria-Florance Kitova
Maria-Florance Kitova
LVLudmila Georgieva Vladimirova-Kitova
Ludmila Georgieva Vladimirova-Kitova
KSKristina Stoyanova
Kristina Stoyanova
Drozdstoy StoyanovDrozdstoy Stoyanov
Drozdstoy Stoyanov
Background: Obesity and depression have a bidirectional relationship. Previous work has shown that obesity increases the risk of depression, while atypical depression can elevate the risk of obesity. This study aimed to investigate the associations between anthropometric markers, lipid and insulin resistance biomarkers, inflammatory cytokines, and adipokines with depressive symptom severity in individuals with newly diagnosed metabolic syndrome (MetS). Methods: 88 treatment-naïve adults with newly identified MetS, without known coronary artery disease, were included. Clinical assessments comprised anthropometric measures, while laboratory analyses measured lipid metabolism markers, insulin resistance indicators, inflammatory cytokines, and adipokines. Depressive symptom severity was assessed using the von Zerssen Depression Scale (DS), validated for the Bulgarian population. To explore latent structures within biomarker domains, principal component analyses (PCA) were performed. Associations between depressive symptoms and biomarkers were then examined in two steps: first, using linear regression with PCA-derived component scores, and second, through hierarchical multiple regression focusing on selected individual biomarkers, controlling for covariates such as age and gender. Results: PCA identified distinct latent structures within anthropometric, lipid, insulin resistance, and cytokine domains, though regression analyses using PCA-derived component scores did not yield significant associations with depressive symptoms (all p > 0.050). Hierarchical multiple regression with selected biomarkers showed that lower low-density lipoprotein cholesterol (LDLc)/Apolipoprotein B (ApoB) ratios were consistently associated with higher depressive symptom severity (Model 1: β = –0.332, p = 0.011; Model 2: β = –0.326, p = 0.012; Model 3: β = –0.319, p = 0.013), while higher interleukin-6 (IL-6) levels were independently linked to greater symptom severity (Model 1: β = 0.217, p = 0.052; Model 3: β = 0.230, p = 0.033). ApoB/apolipoprotein A1 (ApoA1) ratios and age showed weaker or non-significant effects. Conclusions: LDLc/ApoB ratio and IL-6 levels are independently associated with depressive symptom severity in newly diagnosed MetS, highlighting their potential as clinically relevant biomarkers. These findings highlight perspectives for integrating lipid and inflammatory profiles in the assessment of depression risk within MetS populations.

4 January 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
IPIliyana Hristova Petrova
Iliyana Hristova Petrova
AAAlexander Alexandrov
Alexander Alexandrov
GVGeorgi Vladimirov
Georgi Vladimirov
HMHristo Mateev
Hristo Mateev
IBIvaylo Bogov
Ivaylo Bogov
NGNina Gotcheva
Nina Gotcheva
Contrast-induced acute kidney injury (CI-AKI) is a serious complication after angiographic examinations in cardiology. Diagnosis may be delayed based on standard serum creatinine, and subclinical forms of kidney damage may not be detected at all. In our study we investigate the clinical use in these directions of a “damage” type biomarker - Neutrophil Gelatinase-Associated Lipocalin (NGAL). Among patients with a high-risk profile undergoing scheduled coronary angiography and/or angioplasty, plasmsa NGAL was determined at baseline, at 4 and 24 hours after contrast administration. In the CI-AKI group, NGAL increased significantly at the 4th hour (132.33±72.83 ng/ml versus 111.48±65.06 ng/ml, p=0.006) and at the 24th hour (212 .93±276.61 ng/ml, p=0.008). In patients with subclinical CI-AKI, NGAL also increased significantly at the 4th hour (128.18±99 ng/ml, p=0.002) and reached levels close to those in patients with CI-AKI. Unlike new biomarker, however, serum creatinine did not change significantly in this group. The diagnostic power of NGAL is extremely good - AUC 0.847 (95% CI: 0.677-1.000; p=0.001) in CI-AKI and AUC 0.731 (95% CI: 0.539 – 0.924; p=0.024) in subclinical CI-AKI. NGAL may be a reliable biomarker for early diagnosis of clinical and subclinical forms of renal injury after contrast angiographic studies.

7 April 2023 in Bulgarian Cardiology
Verified
Journal Article
Open access
PDF file
AAA. Alexandrov
A. Alexandrov
HMH. Mateev
H. Mateev
GVG. Vladimirov
G. Vladimirov
IBI. Bayraktarova
I. Bayraktarova
IPIliyana Hristova Petrova
Iliyana Hristova Petrova
ИБИ. Байрактарова
И. Байрактарова
Age is an important non-modifi able risk factor for cardiovascular disease. Both European and American guidelines recommend offering an invasive reperfusion strategy in elderly patients with ACS, taking into account the patients‘ comorbidities and baseline level of functioning. Materials and methods: All patients over 80 years of age with acute coronary syndrome, treated in the Department of Invasive Cardiology of the National Heart Hospital for the period between January 1, 2016. and December 31, 2018, are retrospectively analyzed. The primary endpoint was defi ned as all-cause mortality during the hospital stay and at follow-up. Predictors of mortality were assessed and independent predictors were identifi ed. Results: During the study period, 179 patients aged 80 years or older were identifi ed as being treated for ACS with PCI. In the study population, in hospital mortality for the index event was 11.8%. At a mean follow-up time of 20.19 ± 11.9 months, mortality rose signifi cantly to 64.6%. When evaluating in-hospital mortality on multivariate analysis, the two independent predictors were Cardiogenic shock (HR 0.005, 95% CI 0.01–0.44; p < 0.001) and acute/exacerbated renal failure (0.986 95% CI 0.984-0.997; p = 0.015). Conclusion: The present study provides important information regarding characteristics and outcomes in very elderly patients undergoing PCI for ACS. In the future, this subset of patients is predicted to grow, meaning that their approach must be evidence-based to ensure safe and effective treatment options.